Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

New Mutations in ADC-Type β-Lactamases From Acinetobacter Spp. Affect Cefoxitin and Ceftazidime Hydrolysis

  • Pérez, Astrid
  • Pérez-Llarena, Francisco J.
  • García, Patricia
  • Kerff, Frédéric
  • Beceiro Casas, Alejandro
  • Galleni, Moreno
  • Bou, Germán
This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at: https://doi.org/10.1093/JAC/DKU163., [Abstract] Objectives: Two natural variants of ADC-type β-lactamases of Acinetobacter spp., ADC-1 and ADC-5, differ by nine mutations in their protein sequence. ADC-5 hydrolyses cefoxitin better than ADC-1 and the opposite is true for ceftazidime. We produced single and combined mutations in ADC-5 and characterized the variants microbiologically and biochemically to determine which amino acid residues are involved in the hydrolysis of β-lactam antibiotics in this family of β-lactamases. Methods: Site-directed mutagenesis, with blaADC-5 as a source of DNA, was used to generate nine single mutated and three combined mutated enzymes. The proteins (wild-type and derivatives) were then expressed in isogenic conditions in Escherichia coli. MICs of β-lactams were determined using Etest strips. ADC-1, ADC-5, ADC-5-P167S and ADC-5-P167S/D242G/Q163K/G342R were also purified and the kinetic parameters determined for ceftazidime, cefoxitin, cefalotin and ampicillin. Results: Single mutations did not significantly convert the hydrolysis spectrum of the ADC-5 enzyme into that of the ADC-1 enzyme, although among all studied mutants only the quadruple mutant (ADC-5-P167S/D242G/Q163K/G342R) displayed microbiological and biochemical properties consistent with those of ADC-1. Conclusions: Although some single mutations are known to affect cefepime hydrolysis in ADC-type β-lactamases, little is known about ceftazidime and cefoxitin hydrolysis in this family of β-lactamases. Hydrolysis of these antibiotics appears to be positively and negatively affected, respectively, by the Q163K, P167S, D242G and G342R amino acid replacements., This study was funded by grants from the European Community, FP7, ID: 278232 (MagicBullet), and by Plan Nacional de I+D+I 2008–2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), cofinanced by the European Development Regional Fund (EDRF) ‘A Way to Achieve Europe’. It has also been funded by the Fondo de Investigación Sanitaria (grant PI12/00552). F. K. is a research associate of the FRS-FNRS (Brussels, Belgium)
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain

  • Fernández-Martínez, Marta
  • Miró, Elisenda
  • Ortega, Adriana
  • Bou, Germán
  • González-López, Juan José
  • Oliver, Antonio
  • Pascual, Álvaro
  • Cercenado, Emilia
  • Oteo, Jesús
  • Martínez-Martínez, Luis
  • Navarro, Ferrán
Multicenter study, [Abstract] The activity of eight aminoglycosides (amikacin, apramycin, arbekacin, gentamicin, kanamycin, neomycin, netilmicin and tobramycin) against a collection of 257 amoxicillin/clavulanic acid (AMC)-resistant Escherichia coli isolates was determined by microdilution. Aminoglycoside resistance rates, the prevalence of aminoglycoside-modifying enzyme (AME) genes, the relationship between AME gene detection and resistance phenotype to aminoglycosides, and the association of AME genes with mechanisms of AMC resistance in E. coli isolates in Spain were investigated. Aminoglycoside-resistant isolates were screened for the presence of genes encoding common AMEs [aac(3)-Ia, aac(3)-IIa, aac(3)-IVa, aac(6')-Ib, ant(2″)-Ia, ant(4')-IIa and aph(3')-Ia] or 16S rRNA methylases (armA, rmtB, rmtC and npmA). In total, 105 isolates (40.9%) were resistant to at least one of the aminoglycosides tested. Amikacin, apramycin and arbekacin showed better activity, with MIC90 values of 2mg/L (arbekacin) and 8mg/L (amikacin and apramycin). Kanamycin presented the highest MIC90 (128mg/L). The most common AME gene was aac(6')-Ib (36 strains; 34.3%), followed by aph(3')-Ia (31 strains; 29.5%), ant(2″)-Ia (29 strains; 27.6%) and aac(3)-IIa (23 strains; 21.9%). aac(3)-Ia, aac(3)-IVa, ant(4')-IIa and the four methylases were not detected. The ant(2″)-Ia gene was usually associated with OXA-1 [21/30; 70%], whilst 23/25 (92%) strains producing CTX-M-15 had the aac(6')-Ib gene. The most prevalent AME gene was aac(6')-Ib (18/41; 44%) in nosocomial isolates, whilst ant(2″)-Ia and aph(3')-Ia genes (20/64; 31%) were more frequent in strains of community origin. In 64.6% isolates the phenotypic profile correlated with the presence of commonly encountered AMEs., This study was supported by the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, co-financed by the European Development Regional Fund, A Way To Achieve Europe, ERDF; the Spanish Network for the Research in Infectious Diseases [REIPI RD12/0015]; and the Fondo de Investigación Sanitaria [grants PI12/00552, PI11/1117 and PI09/917].
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Reduced susceptibility to biocides in Acinetobacter baumannii: association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps

  • Fernández-Cuenca, Felipe
  • Tomás, María
  • Caballero-Moyano, Francisco-Javier
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Vila, Jordi
  • Pachón, Jerónimo
  • Cisneros, José Miguel
  • Rodríguez-Baño, Jesús
  • Pascual, Álvaro
Multicenter study, [Abstract] Objectives: The objective of this study was to analyse whether there is an association between reduced susceptibility to biocides in Acinetobacter baumannii and (i) antimicrobial resistance (co-resistance), (ii) prevalent (epidemic) clones, (iii) changes in the fitness or (iv) expression of genes related to efflux pumps and porins. Methods: Susceptibility to biocides and antimicrobials was determined in 49 clonally unrelated isolates of A. baumannii. Biological cost, in terms of mean generation time, was determined by spectrophotometry. Quantitative real-time RT-PCR was used to determine the relative expression of genes encoding several efflux pumps and porins. Results: Reduced susceptibility to chlorhexidine digluconate, benzalkonium chloride and Irgasan(®) was associated with resistance to aminoglycosides, tetracycline and ciprofloxacin (P < 0.05). The MICs of carbapenems, aminoglycosides, doxycycline and ciprofloxacin for isolate Ab70 (epidemic clone) exposed to these biocides increased by ≥2 dilutions. Reduced susceptibility to Orsan(®) was more frequent among prevalent clones than non-prevalent clones (P < 0.05). Mean generation times for Ab70 before and after exposure to benzalkonium chloride were 57.8 and 78.1 min, respectively (P = 0.02). Relative expression of abeS and adeB was increased in Ab46 and Ab70 after exposure to chlorhexidine digluconate, but was decreased for ompA and carO after exposure to Irgasan(®). Conclusions: Reduced susceptibility to biocides is associated with co-resistance to carbapenems, aminoglycosides, tetracycline and ciprofloxacin. Reduced susceptibility to Orsan(®) may be a marker of prevalent clones. Acquisition of reduced susceptibility to benzalkonium chloride has a biological cost. Exposure to biocides affects the relative expression of genes related to some efflux pump genes (increased expression) or porins (reduced expression)., This work was supported by the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (projects PI11-02046 and PI10/00056) and the Consejería de Innovación Ciencia y Empresa, Junta de Andalucía (P11-CTS-7730), Spain, by the Plan Nacional de I+D+i 2008-2011 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015)—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem

  • Oteo, Jesús
  • Ortega, Adriana
  • Bartolomé, Rosa
  • Bou, Germán
  • Conejo, María del Carmen
  • Fernández-Martínez, Marta
  • González-López, Juan José
  • Martínez-García, Laura
  • Martínez-Martínez, Luis
  • Merino Carballeira, María
  • Miró, Elisenda
  • Mora-Rillo, Marta
  • Navarro, Ferrán
  • Oliver, Antonio
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
  • Ruiz Carrascoso, Guillermo
  • Ruiz-Garbajosa, Patricia
  • Zamorano, Laura
  • Bautista, Verónica
  • Pérez-Vázquez, María
  • Campos, José
[Abstract] The aim of this study was to determine the impact of carbapenemase-producing Enterobacteriaceae (CPE) in Spain in 2013 by describing the prevalence, dissemination, and geographic distribution of CPE clones, and their population structure and antibiotic susceptibility. From February 2013 to May 2013, 83 hospitals (about 40,000 hospital beds) prospectively collected nonduplicate Enterobacteriaceae using the screening cutoff recommended by EUCAST. Carbapenemase characterization was performed by phenotypic methods and confirmed by PCR and sequencing. Multilocus sequencing types (MLST) were determined for Klebsiella pneumoniae and Escherichia coli. A total of 702 Enterobacteriaceae isolates met the inclusion criteria; 379 (54%) were CPE. OXA-48 (71.5%) and VIM-1 (25.3%) were the most frequent carbapenemases, and K. pneumoniae (74.4%), Enterobacter cloacae (10.3%), and E. coli (8.4%) were the species most affected. Susceptibility to colistin, amikacin, and meropenem was 95.5%, 81.3%, and 74.7%, respectively. The most prevalent sequence types (STs) were ST11 and ST405 for K. pneumoniae and ST131 for E. coli. Forty-five (54.1%) of the hospitals had at least one CPE case. For K. pneumoniae, ST11/OXA-48, ST15/OXA-48, ST405/OXA-48, and ST11/VIM-1 were detected in two or more Spanish provinces. ST11 isolates carried four carbapenemases (VIM-1, OXA-48, KPC-2, and OXA-245), but ST405 isolates carried OXA-48 only. A wide interregional spread of CPE in Spain was observed, mainly due to a few successful clones of OXA-48-producing K. pneumoniae (e.g., ST11 and ST405). The dissemination of OXA-48-producing E. coli is a new finding of public health concern. According to the susceptibilities determined in vitro, most of the CPE (94.5%) had three or more options for antibiotic treatment., This work was supported by a grant from the Fondo de Investigación Sanitaria (grant PI12/01242); the Antibiotic Resistance Surveillance Programme of the Spanish Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad; the Plan Nacional de I+D+I 2008–2011; and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), cofinanced by the European Development Regional Fund (ERDF) “A way to achieve Europe.”
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The Acinetobacter Baumannii OMP33-36 Porin Is a Virulence Factor That Induces Apoptosis and Modulates Autophagy in Human Cells

  • Rumbo, Carlos
  • Tomás, María
  • Fernández-Moreira, Esteban
  • Soares, Nelson C.
  • Carvajal, Micaela
  • Santillana, Elena
  • Beceiro Casas, Alejandro
  • Romero, Antonio
  • Bou, Germán
[Abstract] Acinetobacter baumannii is an extracellular opportunistic human pathogen that is becoming increasingly problematic in hospitals. In the present study, we demonstrate that the A. baumannii Omp 33- to 36-kDa protein (Omp33-36) is a porin that acts as a channel for the passage of water. The protein is found on the cell surface and is released along with other porins in the outer membrane vesicles (OMVs). In immune and connective cell tissue, this protein induced apoptosis by activation of caspases and modulation of autophagy, with the consequent accumulation of p62/SQSTM1 (sequestosome 1) and LC3B-II (confirmed by use of autophagy inhibitors). Blockage of autophagy enables the bacterium to persist intracellularly (inside autophagosomes), with the subsequent development of cytotoxicity. Finally, we used macrophages and a mouse model of systemic infection to confirm that Omp33-36 is a virulence factor in A. baumannii. Overall, the study findings show that Omp33-36 plays an important role in the pathogenesis of A. baumannii infections., This work was supported by Magic Bullet (to G. Bou), a project funded by the European Union's Directorate General for Research and Innovation, through the Seventh Framework Program for Research and Development (grant agreement 278232); the Spanish Network for Research in Infectious Diseases (REIPI-RD12/0015); and Spanish Ministry of Health/FEDER funding (ISCIII-FIS PI12/00552 to G. Bou, FIS PI10/00056 and PI13/02390 to M. Tomás).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Role of Acinetobacter Baumannii UmuD Homologs in Antibiotic Resistance Acquired Through DNA Damage-Induced Mutagenesis

  • Aranda Rodríguez, Jesús
  • López, Mario
  • Leiva, Enoy
  • Magán, Andrés
  • Adler, Ben
  • Bou, Germán
  • Barbé, Jordi
[Abstract] The role of Acinetobacter baumannii ATCC 17978 UmuDC homologs A1S_0636-A1S_0637, A1S_1174-A1S_1173, and A1S_1389 (UmuDAb) in antibiotic resistance acquired through UV-induced mutagenesis was evaluated. Neither the growth rate nor the UV-related survival of any of the three mutants was significantly different from that of the wild-type parental strain. However, all mutants, and especially the umuDAb mutant, were less able to acquire resistance to rifampin and streptomycin through the activities of their error-prone DNA polymerases. Furthermore, in the A. baumannii mutant defective in the umuDAb gene, the spectrum of mutations included a dramatic reduction in the frequency of transition mutations, the mutagenic signature of the DNA polymerase V encoded by umuDC., This study was funded by grants from the Ministerio de Ciencia e Innovación (BFU2011-23478); the European Community, FP 7, ID: 278232 (Magic Bullet); the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III—cofinanced by the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015) and FIS PI12/00552. J.A. is the recipient of a Sara Borrell postdoctoral grant from the Instituto de Salud Carlos III (Madrid, Spain).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Inhibitor-Resistant TEM- And OXA-1-Producing Escherichia Coli Isolates Resistant to Amoxicillin-Clavulanate Are More Clonal and Possess Lower Virulence Gene Content Than Susceptible Clinical Isolates

  • Oteo, Jesús
  • González-López, Juan José
  • Ortega, Adriana
  • Quintero-Zárate, Natalia
  • Bou, Germán
  • Cercenado, Emilia
  • Conejo, María del Carmen
  • Martínez-Martínez, Luis
  • Navarro, Ferrán
  • Oliver, Antonio
  • Bartolomé, Rosa
  • Campos, José
[Abstract] In a previous prospective multicenter study in Spain, we found that OXA-1 and inhibitor-resistant TEM (IRT) β-lactamases constitute the most common plasmid-borne mechanisms of genuine amoxicillin-clavulanate (AMC) resistance in Escherichia coli. In the present study, we investigated the population structure and virulence traits of clinical AMC-resistant E. coli strains expressing OXA-1 or IRT and compared these traits to those in a control group of clinical AMC-susceptible E. coli isolates. All OXA-1-producing (n = 67) and IRT-producing (n = 45) isolates were matched by geographical and temporal origin to the AMC-susceptible control set (n = 56). We performed multilocus sequence typing and phylogenetic group characterization for each isolate and then studied the isolates for the presence of 49 virulence factors (VFs) by PCR and sequencing. The most prevalent clone detected was distinct for each group: group C isolates of sequence type (ST) 88 (C/ST88) were the most common in OXA-1 producers, B2/ST131 isolates were the most common in IRT producers, and B2/ST73 isolates were the most common in AMC-susceptible isolates. The median numbers of isolates per ST were 3.72 in OXA-1 producers, 2.04 in IRT producers, and 1.69 in AMC-susceptible isolates; the proportions of STs represented by one unique isolate in each group were 19.4%, 31.1%, and 48.2%, respectively. The sum of all VFs detected, calculated as a virulence score, was significantly higher in AMC-susceptible isolates than OXA-1 and IRT producers (means, 12.5 versus 8.3 and 8.2, respectively). Our findings suggest that IRT- and OXA-1-producing E. coli isolates resistant to AMC have a different and less diverse population structure than AMC-susceptible clinical E. coli isolates. The AMC-susceptible population also contains more VFs than AMC-resistant isolates., This study was supported by the Plan Nacional de I+D+i 2008-2011 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015). The study was cofinanced by the European Development Regional Fund (ERDF; A way to achieve Europe) and the Fondo de Investigación Sanitaria (grant PI09/0917).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Monotherapy Versus Combination Therapy for Sepsis Due to Multidrug-Resistant Acinetobacter Baumannii: Analysis of a Multicentre Prospective Cohort

  • López-Cortés, Luis Eduardo
  • Cisneros, José Miguel
  • Fernández-Cuenca, Felipe
  • Bou, Germán
  • Tomás, María
  • Garnacho-Montero, José
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Vila, Jordi
  • Pachón, Jerónimo
  • Rodríguez-Baño, Jesús
Observational study, This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at: https://doi.org/10.1093/JAC/DKU233., [Abstract] Background: Treatment of multidrug-resistant Acinetobacter baumannii (MDRAB) infection presents a challenge because of the scarcity of available options. Even though combination therapy (CT) is frequently used in clinical practice, data are needed to support its use instead of monotherapy (MT). Methods: A prospective observational study was conducted in 28 Spanish hospitals. Patients with sepsis caused by MDRAB, defined according to strict criteria, and who received active antibiotic treatment (according to in vitro susceptibility testing) for at least 48 h, were included. The main outcome variable was all-cause 30 day mortality after initiation of targeted therapy. Multivariate analysis, including a propensity score (for receiving CT), was performed by Cox regression. Results: One hundred and one patients were included in the analysis; 68 (67.3%) received MT and 33 (32.7%) received CT. Pneumonia was the most common infection (50.5%), 68.6% of cases being associated with mechanical ventilation. Colistin (67.6%) and carbapenems (14.7%) were the most common drugs used in MT; colistin plus tigecycline (27.3%) and carbapenem plus tigecycline (12.1%) were the most frequent combinations. Crude 30 day mortality was 23.5% and 24.2% for the MT and CT groups, respectively (RR = 1.03; 95% CI 0.49-2.16; P = 0.94). Multivariate analysis of 30 day survival showed no trend towards reduced 30 day mortality with CT (HR = 1.35; 95% CI 0.53-3.44; P = 0.53). Subgroup analysis showed similar results. Conclusions: Our data do not support an association of CT with reduced mortality in MDRAB infections. More data for specific types of infection and combinations are needed., Supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III–co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), and ‘Fondo de Investigaciones Sanitarias and Fondos Europeos de Desarrollo Regional-FEDER’ (PI10/00056 and PI11/02046). M. T. was financially supported by the Miguel Servet Programme (C.H.U.A Coruña and ISCIII).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

OXA-207, a Novel OXA-24 Variant With Reduced Catalytic Efficiency Against Carbapenems in Acinetobacter Pittii From Spain

  • Cayo, Rodrigo
  • Merino Carballeira, María
  • Ruiz del Castillo, Belén
  • Cano, María E.
  • García Calvo-Montes, Jorge
  • Bou, Germán
  • Martínez-Martínez, Luis
Brief report, [Abstract] A carbapenem-resistant Acinetobacter pittii strain carrying an OXA-24-like enzyme was isolated in northern Spain in 2008. Sequence analysis confirmed the presence of the novel bla(OXA-207) gene flanked by the site-specific XerC/XerD-like recombination binding sites and showing a unique Gly222Val substitution compared to OXA-24. Cloning and kinetic analysis showed that OXA-207 presents a reduction in the catalytic efficiency against carbapenems and a noticeable increase for oxacillin., This work was partially supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III - cofinanced by the European Development Regional Fund “A way to achieve Europe” ERDF, the Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), and by the Fondo de Investigación Sanitaria (PI080209, PS09/00687, and PI12/00552). We are grateful to the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), which gave a PDEE grant to R.C. (protocol 4149/08-4).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii

  • Beceiro Casas, Alejandro
  • Moreno-Flores, Antonio
  • Fernández, Natalia
  • Vallejo, J. A.
  • Aranda Rodríguez, Jesús
  • Adler, Ben
  • Harper, Marina
  • Boyce, John Dallas
  • Bou, Germán
[Abstract] Two mechanisms of resistance to colistin have been described in Acinetobacter baumannii. One involves complete loss of lipopolysaccharide (LPS), resulting from mutations in lpxA, lpxC, or lpxD, and the second is associated with phosphoethanolamine addition to LPS, mediated through mutations in pmrAB. In order to assess the clinical impacts of both resistance mechanisms, A. baumannii ATCC 19606 and its isogenic derivatives, AL1851 ΔlpxA, AL1852 ΔlpxD, AL1842 ΔlpxC, and ATCC 19606 pmrB, were analyzed for in vitro growth rate, in vitro and in vivo competitive growth, infection of A549 respiratory alveolar epithelial cells, virulence in the Caenorhabditis elegans model, and virulence in a systemic mouse infection model. The in vitro growth rate of the lpx mutants was clearly diminished; furthermore, in vitro and in vivo competitive-growth experiments revealed a reduction in fitness for both mutant types. Infection of A549 cells with ATCC 19606 or the pmrB mutant resulted in greater loss of viability than with lpx mutants. Finally, the lpx mutants were highly attenuated in both the C. elegans and mouse infection models, while the pmrB mutant was attenuated only in the C. elegans model. In summary, while colistin resistance in A. baumannii confers a clear selective advantage in the presence of colistin treatment, it causes a noticeable cost in terms of overall fitness and virulence, with a more striking reduction associated with LPS loss than with phosphoethanolamine addition. Therefore, we hypothesize that colistin resistance mediated by changes in pmrAB will be more likely to arise in clinical settings in patients treated with colistin., This study was funded by grants from the European Community, FP 7 (ID, 278232) (MagicBullet); the Ministerio de Ciencia e Innovación; Instituto de Salud Carlos III, cofinanced by the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015); and Fondo de Investigación Sanitaria (grant PI12/00552).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

N-acetylcysteine selectively antagonizes the activity of imipenem in Pseudomonas aeruginosa by an OprD-mediated mechanism

  • Rodríguez-Beltrán, Jerónimo
  • Cabot, Gabriel
  • Valencia, Estela Ynés
  • Costas, Coloma
  • Bou, Germán
  • Oliver, Antonio
  • Blázquez, Jesús
[Abstract] The modulating effect of N-acetylcysteine (NAC) on the activity of different antibiotics has been studied in Pseudomonas aeruginosa. Our results demonstrate that, in contrast to previous reports, only the activity of imipenem is clearly affected by NAC. MIC and checkerboard determinations indicate that the NAC-based modulation of imipenem activity is dependent mainly on OprD. SDS-PAGE of outer membrane proteins (OMPs) after NAC treatments demonstrates that NAC does not modify the expression of OprD, suggesting that NAC competitively inhibits the uptake of imipenem through OprD. Similar effects on imipenem activity were obtained with P. aeruginosa clinical isolates. Our results indicate that imipenem-susceptible P. aeruginosa strains become resistant upon simultaneous treatment with NAC and imipenem. Moreover, the generality of the observed effects of NAC on antibiotic activity was assessed with two additional bacterial species, Escherichia coli and Acinetobacter baumannii. Caution should be taken during treatments, as the activity of imipenem may be modified by physiologically attainable concentrations of NAC, particularly during intravenous and nebulized regimes., This work was supported by the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), and FIS grant PI13/00063. E.Y.V was funded by a postdoctoral fellowship from CNPq-Brazil (CNPq 236914/2012-0).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Characterization of plasmids carrying the blaOXA-24/40 carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system

  • Mosqueda, Noraida
  • Gato, Eva
  • Roca, Ignasi
  • Zamora López, María José
  • Ruiz de Alegría-Puig, Carlos
  • Fernández-Cuenca, Felipe
  • Martínez-Martínez, Luis
  • Pachón, Jerónimo
  • Cisneros, José Miguel
  • Rodríguez-Baño, Jesús
  • Pascual, Álvaro
  • Vila, Jordi
  • Bou, Germán
  • Tomás, María
[Abstract] Background: Carbapenem-resistant Acinetobacter baumannii (CRAb) is a major source of nosocomial infections in Spain associated with the production of OXA-58-like or OXA-24/40-like β-lactamase enzymes. We analysed the plasmids carrying the bla(OXA-24/40)-like gene in CRAb isolates obtained a decade apart. Methods: The presence of β-lactamases was screened for by PCR (metallo-β-lactamases, carbapenem-hydrolysing class D β-lactamases, GES and KPC) in 101 CRAb isolates obtained in two multicentre studies (GEIH/REIPI-Ab-2000 and GEIH/REIPI-Ab-2010; n = 493 Acinetobacter spp). We analysed the distribution and characterization of the plasmids carrying the bla(OXA-24/40)-like gene and sequenced two plasmids, AbATCC223p (2000) and AbATCC329p (2010) from A. baumannii ATCC 17978 transformants. Results: Acquisition of the bla(OXA-24/40)-like gene was the main mechanism underlying resistance to carbapenems (48.7% in 2000 compared with 51.6% in 2010). This gene was mainly isolated in ST2 A. baumannii strains in both studies, although some novel STs (ST79 and ST80) appeared in 2010. The gene was located in plasmids (8-12 kbp) associated with the repAci2 or repAci2/repGR12 types. The sequences of AbATCC223p (8840 bp) and AbATCC329p (8842 bp) plasmids were similar, particularly regarding the presence of the genes encoding the AbkA/AbkB proteins associated with the toxin/antitoxin system. Moreover, the abkA/abkB gene sequences (>96% identity) were also located in plasmids harbouring the bla(OXA-58)-like gene. Conclusions: The action of OXA-24/40 and OXA-58 β-lactamase-like enzymes represents the main mechanism underlying resistance to carbapenems in Spain in the last decade. AbkA/AbkB proteins in the toxin/antitoxin system may be involved in the successful dissemination of plasmids carrying the bla(OXA-24/40)-like gene, and probably also the bla(OXA-58)-like gene, thus contributing to the plasmid stability., This work was financially supported by Instituto de Salud Carlos III FEDER, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015) by funding from the European Community (TROCAR contract HEALTH-F3-2008-223031) and by the Spanish Ministry of Health and FEDER funding (FIS PI10/00056-PI13/02390 to M. T. and PI12/00552 to G. B.). M. T. was financially supported by the Miguel Servet Programme (C.H.U.A Coruña and ISCIII).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Diagnosis and Antimicrobial Treatment of Invasive Infections Due to Multidrug-Resistant Enterobacteriaceae: Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology

  • Rodríguez-Baño, Jesús
  • Cisneros, José Miguel
  • Cobos-Trigueros, Nazaret
  • Fresco, Gema
  • Navarro-San Francisco, Carolina
  • Gudiol, Carlota
  • Horcajada, Juan Pablo
  • López-Cerero, Lorena
  • Serrano Martínez, José Antonio
  • Molina Gil-Bermejo, José
  • Montero, Milagro
  • Paño-Pardo, José Ramón
  • Pascual, Álvaro
  • Peña, Carmen
  • Pintado, Vicente
  • Retamar-Gentil, Pilar
  • Tomás, María
  • Borges-Sá, Márcio M.
  • Garnacho-Montero, José
  • Bou, Germán
Practice guideline, [Abstract] The spread of multidrug-resistant Enterobacteriaceae related to the production of extended-spectrum β-lactamases and carbapenemases is a serious public health problem worldwide. Microbiological diagnosis and therapy of these infections are challenging and controversial. Clinically relevant questions were selected and the literature was reviewed for each of them. The information from the selected articles was extracted and recommendations were provided and graded according to the strength of the recommendations and quality of the evidence. The document was opened to comments from the members from the Spanish Society of Infectious Diseases and Clinical Microbiology, which were considered for inclusion in the final version. Evidence-based recommendations are provided for the use of microbiological techniques for the detection of extended-spectrum β-lactamases and carbapenemases in Enterobacteriaceae, and for antibiotic therapy for invasive/severe infections caused by these organisms. The absence of randomised controlled trials is noteworthy; thus, recommendations are mainly based on observational studies (that have important methodological limitations), pharmacokinetic and pharmacodynamics models, and data from animal studies. Additionally, areas for future research were identified., [Resumen] La diseminación de Enterobacteriaceae multirresistentes en relación con la producción de β-lactamasas de espectro extendido y carbapenemasas es un importante problema de salud pública en todo el mundo. Tanto el diagnóstico microbiológico como el tratamiento de estas infecciones son complicados y controvertidos. Los autores seleccionaron preguntas clínicamente relevantes, realizándose una revisión de la literatura para cada una de ellas; se obtuvo información de los artículos seleccionados y se realizaron recomendaciones que se clasificaron de acuerdo con la fuerza de la recomendación y la calidad de la evidencia. El documento estuvo abierto para los comentarios de los socios de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, los cuales se consideraronpara su inclusión en la versión final. Se proporcionan recomendaciones basadas en la evidencia para el uso de técnicas microbiológicas cara a la detección de β-lactamasas de espectro extendido y carbapenemasas en Enterobacteriaceae, y para el tratamiento antimicrobiano de las infecciones graves o invasivas causadas por estos microorganismos. Es llamativa la ausencia de ensayos aleatorizados, por lo que las recomendaciones se basan principalmente en estudios observacionales que tienen importantes limitaciones metodológicas, modelos farmacocinéticos y farmacodinámicos, y datos de estudios en animales. Además, se identificaron áreas prioritarias para la investigación futura., Supported by the Spanish Society of Clinical Microbiology and Infectious Diseases, and Ministerio de Economía y Competitividad, Instituto de Salud Carlos III – co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vitro and in vivo activities of -lactams in combination with the novel -lactam enhancers zidebactam and WCK 5153 against multidrug-resistant metallo-lactamase-producing klebsiella pneumoniae

  • Moya, Bartolomé
  • Barceló, Isabel M.
  • Cabot, Gabriel
  • Torrens Ribot, Gabriel
  • Palwe, Snehal
  • Joshi, Prashant
  • Umarkar, Kushal
  • Takalkar, Swapna
  • Periasamy, Hariharan
  • Bhagwat, Sachin
  • Patel, Mahesh
  • Bou, Germán
  • Oliver, Antonio
[Abstract] Zidebactam and WCK 5153 are novel bicyclo-acyl hydrazide (BCH) agents that have previously been shown to act as β-lactam enhancer (BLE) antibiotics in Pseudomonas aeruginosa and Acinetobacter baumannii The objectives of this work were to identify the molecular targets of these BCHs in Klebsiella pneumoniae and to investigate their potential BLE activity for cefepime and aztreonam against metallo-β-lactamase (MBL)-producing strains in vitro and in vivo Penicillin binding protein (PBP) binding profiles were determined by Bocillin FL assay, and 50% inhibitory concentrations (IC50s) were determined using ImageQuant TL software. MICs and kill kinetics for zidebactam, WCK 5153, and cefepime or aztreonam, alone and in combination, were determined against clinical K. pneumoniae isolates producing MBLs VIM-1 or NDM-1 (plus ESBLs and class C β-lactamases) to assess the in vitro enhancer effect of BCH compounds in conjunction with β-lactams. Additionally, murine systemic and thigh infection studies were conducted to evaluate BLE effects in vivo Zidebactam and WCK 5153 showed specific, high PBP2 affinity in K. pneumoniae The MICs of BLEs were >64 μg/ml for all MBL-producing strains. Time-kill studies showed that a combination of these BLEs with either cefepime or aztreonam provided 1 to >3 log10 kill against MBL-producing K. pneumoniae strains. Furthermore, the bactericidal synergy observed for these BLE-β-lactam combinations translated well into in vivo efficacy even in the absence of MBL inhibition by BLEs, a characteristic feature of the β-lactam enhancer mechanism of action. Zidebactam and WCK 5153 are potent PBP2 inhibitors and display in vitro and in vivo BLE effects against multidrug-resistant (MDR) K. pneumoniae clinical isolates producing MBLs., This work was supported by Wockhardt Bio AG, Switzerland, and by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund A Way to Achieve Europe ERDF through the Spanish Network for Research in Infectious Diseases (grants number RD12/0015 and RD16/0016).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance

  • Fernández-Ruiz, Mario
  • Puig-Asensio, Mireia
  • Guinea, Jesús
  • Almirante, Benito
  • Padilla, Belén
  • Almela, Manuel
  • Díaz-Martín, Ana
  • Rodríguez-Baño, Jesús
  • Cuenca-Estrella, Manuel
  • Aguado, José María
  • GEIH-GEMICOMED (SEIMC)
  • Ruiz Pérez de Pipaón, Maite
  • Garnacho, José
  • Red Española de Investigación en Patología Infecciosa
[Objective] To assess the current clinical features and determinants of outcome of Candida tropicalis bloodstream infection (BSI)., [Methods] A population-based surveillance on Candida BSI was conducted from May 2010 to April 2011 in 29 Spanish hospitals. Antifungal susceptibility testing (EUCAST methodology) was centrally performed. The characteristics and outcome of C. tropicalis BSI episodes were compared with those due to other species., [Results] Fifty-nine out of 752 episodes (7.8%) were due to C. tropicalis (annual incidence: 0.62 cases per 100,000 population). Resistance to fluconazole and voriconazole was found in 23.2% and 26.8% of isolates. Breakthrough BSI occurred in 10.5% of episodes. Risk factors for C. tropicalis BSI were age (odds ratio [OR]: 1.01; P-value = 0.05), underlying leukaemia (OR: 4.77; P-value = 0.001) and chronic lung disease (OR: 2.62; P-value = 0.002). There were no differences in clinical failure (persistent BSI for ≥72 h after initiation of therapy and/or 30-day all-cause mortality) between C. tropicalis (39.6%) and non-C. tropicalis groups (45.6%). The appropriateness of antifungal therapy or the fluconazole MIC values had no significant impact on outcome, whereas early central venous catheter removal exerted a protective effect., [Conclusions] C. tropicalis BSI was associated with advanced age, haematological malignancy and respiratory comorbidity. We found no correlation between the unexpectedly high resistance rate to azoles observed and outcome., This work was supported by non-restrictive research grants from Gilead, MSD, Astellas, and Pfizer. This study was cofounded by Fundación SEIMC-GESIDA, by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (co-financed by the European Development Regional Fund [ERDF] “A way to achieve Europe”), and by the Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Challenges to accurate susceptibility testing and interpretation of quinolone resistance in Enterobacteriaceae: results of a Spanish multicentre study

  • Rodríguez-Martínez, José-Manuel
  • Machuca, Jesús
  • Calvo, Jorge
  • Díaz-de-Alba, Paula
  • Rodríguez-Mirones, Cristina
  • Gimeno, Concha
  • Martínez-Martínez, Luis
  • Pascual, Álvaro
[Objectives] The objective of this study was to evaluate the proficiency of Spanish laboratories with respect to accurate susceptibility testing and the detection and interpretation of quinolone resistance phenotypes in Enterobacteriaceae., [Methods] Thirteen strains of Enterobacteriaceae were sent to 62 participating centres throughout Spain; strains harboured GyrA/ParC modifications, reduced permeability and/or plasmid-mediated quinolone resistance genes. The centres were requested to evaluate nalidixic acid and five quinolones, provide raw/interpreted clinical categories and to detect/infer resistance mechanisms. Consensus results from reference centres were used to assign minor, major and very major errors (mEs, MEs and VMEs, respectively)., [Results] Susceptibility testing in the participating centres was frequently performed using the MicroScan WalkAway, Vitek 2 and Wider systems (48%, 30% and 8%, respectively). CLSI/EUCAST breakpoints were used in 71%/29% of the determinations. The percentage of VMEs for all quinolones was well below 2%. Only ofloxacin and moxifloxacin showed higher values for raw VMEs (6.6%), which decreased to 0% and 2.9%, respectively, in the interpreted VMEs. These errors were particularly associated with the CC-03 strain [qnrS2 + aac(6′)-Ib-cr]. For MEs, percentages were always <10%, except in the case of ofloxacin and nalidixic acid. There was a significantly higher percentage of all types of errors for strains whose MICs were at the border of clinical breakpoints., [Conclusion] The use of different breakpoints and methods, the complexity of mutation-driven and transferable resistance mechanisms and the absence of specific tests for detecting low-level resistance lead to high variability and represent a challenge to accuracy in susceptibility testing, particularly in strains with MICs on the border of clinical breakpoints., This work was supported by the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (projects PI11-00934 and PI11/01117) and the Consejería de Innovación Ciencia y Empresa, Junta de Andalucía (P11-CTS-7730), Spain, by the Plan Nacional de I+D+i 2008-2011 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015)—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF., Peer reviewed